Hide metadata

Nivolumab in Combination with Ipilimumab versus Nivolumab Monotherapy as First Line Treatment for Advanced Malignant Melanoma: A Cost-Utility Analysis from a Norwegian Healthcare Perspective

dc.contributor.authorSun, Yu-Lan
dc.date.accessioned2021-10-06T22:00:48Z
dc.date.issued2021
dc.identifier.citationSun, Yu-Lan. Nivolumab in Combination with Ipilimumab versus Nivolumab Monotherapy as First Line Treatment for Advanced Malignant Melanoma: A Cost-Utility Analysis from a Norwegian Healthcare Perspective. Master thesis, University of Oslo, 2021
dc.identifier.urihttp://hdl.handle.net/10852/88786
dc.description.abstracteng
dc.language.isoeng
dc.subject
dc.titleNivolumab in Combination with Ipilimumab versus Nivolumab Monotherapy as First Line Treatment for Advanced Malignant Melanoma: A Cost-Utility Analysis from a Norwegian Healthcare Perspectiveeng
dc.typeMaster thesis
dc.date.updated2021-10-06T22:00:47Z
dc.creator.authorSun, Yu-Lan
dc.date.embargoenddate3021-06-30
dc.rights.termsKLAUSULERING: Dokumentet er klausulert grunnet lovpålagt taushetsplikt. Tilgangskode/Access code C
dc.identifier.urnURN:NBN:no-91430
dc.type.documentMasteroppgave
dc.rights.accessrightsclosedaccess
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/88786/1/thesis.pdf


Files in this item

Name:
thesis.pdf
Size:
79.33Kb
Format:
application/
View/Open

Appears in the following Collection

Hide metadata